Gyre Therapeutics, Inc. GYRE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Gyre Pharmaceuticals | $117.05M+16.3% | $116.59M+10.2% | $107.27M+2.1% | $102.19M-8.4% | $100.64M-13.0% | |
| Other Nonoperating Income Expense by Business | ||||||
| Gyre | $113K+132% | -$33K+90.2% | $154K+175% | -$134K+33.3% | -$351K-144% | |
| Gyre Pharmaceuticals | -$1.7M-27.6% | -$1.47M-10.8% | -$1.11M-451% | -$1.62M-219% | -$1.33M-52.3% | |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest by Business | ||||||
| All Other Segments | -$22K— | -$19K— | —— | —— | —— | |
| Gyre | -$12.03M— | -$5.19M— | —— | —— | —— | |
| Gyre Pharmaceuticals | $8.34M-34.3% | $15.09M-9.6% | $15.83M-15.4% | $13.12M-25.8% | $12.69M-32.2% | |
| Operating Income by Business | ||||||
| All Other Segments | -$22K— | -$19K— | —— | —— | —— | |
| Gyre | -$13.31M-122% | -$8.49M-44.9% | -$7.03M+73.4% | -$6.91M+85.2% | -$6M+91.1% | |
| Gyre Pharmaceuticals | $13.19M-19.5% | $19.99M-9.2% | $19.07M-3.6% | $16.26M-38.6% | $16.37M-40.8% | |
| Operating Expenses by Business | ||||||
| All Other Segments | $22K— | $19K— | —— | —— | —— | |
| Gyre | $13.31M+122% | $8.49M+44.9% | $7.03M-73.4% | $6.91M-85.2% | $6M-91.1% | |
| Gyre Pharmaceuticals | $104.76M+22.9% | $97.49M+16.4% | $88.12M+7.7% | $86.53M+6.3% | $85.25M+1.4% | |
| Income Tax Expense Benefit by Business | ||||||
| Gyre Pharmaceuticals | $4.27M+16.4% | $4.55M-14.4% | $3.46M-52.3% | $2.84M-65.8% | $3.67M-58.9% | |
| Cost of Goods Sold by Business | ||||||
| Gyre Pharmaceuticals | $5.75M+51.3% | $5.42M+39.4% | $4.85M+22.6% | $4.18M-0.1% | $3.8M-15.4% | |
| Total Assets by Business | ||||||
| All Other Segments | $1.44M-43.9% | $1.44M-53.5% | $1.46M-60.1% | $2.01M— | $2.56M— | |
| Gyre | $111.81M+186% | $94.58M+116% | $78M+66.7% | $59.65M— | $39.04M— | |
| Gyre Pharmaceuticals | $526.93M+14.6% | $511.93M+14.6% | $487.77M+12.3% | $471.42M— | $459.77M— | |
| Selling And Marketing Expense by Business | ||||||
| Gyre Pharmaceuticals | $68.47M+22.7% | $65.18M+13.3% | $58.22M+1.9% | $56.59M-1.3% | $55.81M-8.4% | |
| Research And Development Expense Excluding Acquired In Process Cost by Business | ||||||
| Gyre Pharmaceuticals | $14.94M+22.0% | $12.5M+11.4% | $12.1M-0.2% | $12.5M-0.6% | $12.24M-6.3% | |
| Gyre | $2.4M+246% | $1.2M+49.4% | $498K-28.2% | $503K+2.2% | $693K+196% | |
| General And Administrative Expense by Business | ||||||
| All Other Segments | $22K— | $19K— | —— | —— | —— | |
| Gyre | $8.35M+57.3% | $7.29M+44.2% | $6.53M+32.9% | $6.41M+38.6% | $5.31M+5.1% | |
| Gyre Pharmaceuticals | $14.7M+19.0% | $13.49M+22.1% | $13.03M+10.0% | $12.66M+17.4% | $12.35M+31.3% | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| Gyre Pharmaceuticals | $1.25M-45.1% | $1.19M-49.7% | $1.05M-77.7% | $1.07M-82.1% | $2.27M-67.5% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| Gyre | $3.05M+144% | $2.61M+214% | $2.36M+70.3% | $1.79M-21.2% | $1.25M-63.0% | |
| Gyre Pharmaceuticals | $6.18M— | $4.55M— | —— | —— | —— | |
| Fair Value Adjustment Of Warrants by Business | ||||||
| Gyre | -$541K+89.5% | -$2.71M+62.2% | -$2.64M+43.4% | -$2.43M+5.3% | -$5.13M-293% | |
| Revenue (Gross) by Product | ||||||
| Contiva | $5.52M— | $5.52M— | —— | —— | —— | |
| Concentration Risk % by Product | ||||||
| Contiva | 14.4%— | 11.9%— | —— | —— | —— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 280— | 280— | —— | —— | —— | |
| Shanghai | 896— | 896— | —— | —— | —— | |
| Zhengzhou | 720— | 720— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
